Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

101. Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT

Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} The competency framework conferred no clinical benefit, compared to treatment as usual, in reducing seizure severity in adults with epilepsy and learning disability. {{author}} {{($index , , , , , , , , , , , , , , , & . Howard Ring 1, 2, 3, * , James Howlett 4 , Mark Pennington 5 , Christopher Smith 1 , Marcus Redley 1, 3, 6 , Caroline Murphy 7 , Roxanne

2018 NIHR HTA programme

102. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial (Abstract)

Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial To evaluate the effect of a stress-reduction intervention in participants with medication-resistant epilepsy.Adults with medication-resistant focal epilepsy (n = 66) were recruited from 3 centers and randomized to 1 of 2 interventions: (1) progressive muscle relaxation (PMR) with diaphragmatic breathing, or (2) control focused-attention activity with extremity movements. Following an 8-week baseline

2018 EvidenceUpdates

103. Care delivery and self-management strategies for children with epilepsy. Full Text available with Trip Pro

Care delivery and self-management strategies for children with epilepsy. In response to criticism that epilepsy care for children has little impact, healthcare professionals and administrators have developed various service models and strategies to address perceived inadequacies.To assess the effects of any specialised or dedicated intervention for epilepsy versus usual care in children with epilepsy and in their families.We searched the Cochrane Epilepsy Group Specialized Register (27 (...) September 2016), the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 9) in the Cochrane Library, MEDLINE (1946 to 27 September 2016), Embase (1974 to 27 September 2016), PsycINFO (1887 to 27 September 2016) and CINAHL Plus (1937 to 27 September 2016). In addition, we also searched clinical trials registries for ongoing or recently completed trials, contacted experts in the field to seek information on unpublished and ongoing studies, checked the websites of epilepsy organisations

2018 Cochrane

104. Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy Full Text available with Trip Pro

Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy Adults treated with topiramate may develop nephrolithiasis, but its frequency in children on topiramate is unknown. Topiramate inhibits renal carbonic anhydrase, which can lead to renal tubular acidosis and hypercalciuria. We studied 40 consecutive children who initiated topiramate therapy for seizures between January 1997 and February 2003, followed for a mean of 36 months.Serum electrolytes, urinary

2018 Kidney international reports

105. Polysomnographic Aspects of Sleep Architecture on Self-limited Epilepsy with Centrotemporal Spikes: A Systematic Review and Meta-analysis. Full Text available with Trip Pro

Polysomnographic Aspects of Sleep Architecture on Self-limited Epilepsy with Centrotemporal Spikes: A Systematic Review and Meta-analysis. Self-limited epilepsy with centrotemporal spikes is the most common paediatric epileptic syndrome, with growing evidence linking it to various degrees and presentations of neuropsychological dysfunction. The objective of this study is to evaluate the possible sleep macro and microstructural alterations in children with this diagnosis. A systematic review (...) of published manuscripts was carried out in Medline, LILACS and Scielo databases, using the MeSH terms epilepsy, sleep and polysomnography. From 753 retrieved references, 5 were selected, and data from macro and, when available, microstructure of sleep were extracted. Meta-analysis was performed with data from 4 studies using standardized mean difference. Findings were heterogeneous between studies, being the most frequent macrostructural findings a smaller proportion and greater latency of REM sleep

2018 Sleep science (Sao Paulo, Brazil)

106. Five and 10 minute Apgar scores and risks of cerebral palsy and epilepsy: population based cohort study in Sweden. Full Text available with Trip Pro

Five and 10 minute Apgar scores and risks of cerebral palsy and epilepsy: population based cohort study in Sweden. To investigate associations between Apgar score at five and 10 minutes across the entire range of score values (from 0 to 10) and risks of childhood cerebral palsy or epilepsy, and to analyse the effect of changes in Apgar scores from five to 10 minutes after birth in infants born ≥37 completed weeks.Population based cohort study in Sweden, including 1 213 470 non-malformed live (...) singleton infants, born at term between 1999 and 2012. Data on maternal and pregnancy characteristics and diagnoses of cerebral palsy and epilepsy were obtained by individual record linkages of nationwide Swedish registries.Apgar scores at five and 10 minutes.Cerebral palsy and epilepsy diagnosed up to 16 years of age. Adjusted hazard ratios were calculated, along with 95% confidence intervals.1221 (0.1%) children were diagnosed as having cerebral palsy and 3975 (0.3%) as having epilepsy. Compared

2018 BMJ

107. Monarch external Trigeminal Nerve Stimulation System for drug-refractory epilepsy

Monarch external Trigeminal Nerve Stimulation System for drug-refractory epilepsy HealthPACT Health Policy Advisory Committee on Technology Australia and New Zealand Technology Brief 90Y Zevalin for the treatment of non-Hodgkin’s lymphoma (v1.0) August 2011 © State of Queensland (Queensland Health) 2011 This work is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 2.5 Australia licence. In essence, you are free to copy and communicate the work in its current form

2018 COAG Health Council - Horizon Scanning Technology Briefs

108. Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised prospective clinical trial (Abstract)

Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised prospective clinical trial To compare the effects of different surgical approaches for selective amygdalohippocampectomy in patients with pharmacoresistant mesial temporal lobe epilepsy with regard to the neuropsychological outcome and to replicate an earlier study employing a matched-pair design.47 patients were randomised (...) to subtemporal versus transsylvian approaches. Memory, language, attentional and executive functions were assessed before and 1 year after surgery. Multivariate analyses of variance (MANOVAs) with presurgical and postsurgical assessments as within-subject variables and approach and side of surgery as between-subject factors were calculated. Additionally, the frequencies of individual performance changes based on reliable change indices were analysed.Seizure freedom International League Against Epilepsy (ILAE

2018 EvidenceUpdates

109. Losigamone add-on therapy for focal epilepsy. Full Text available with Trip Pro

Losigamone add-on therapy for focal epilepsy. Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and they usually require treatment with a combination of two or more AEDs. In recent years, many newer AEDs have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review (...) . This is an update of a Cochrane review first published in 2012 (Cochrane Database of Systematic Reviews 2012, Issue 6) and updated in 2015.To investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.For the latest update on 9 February 2017, we searched the Cochrane Epilepsy Specialized Register, CENTRAL and MEDLINE . We searched trials registers and contacted the manufacturer of losigamone and authors of included studies for additional information. We did not impose

2018 Cochrane

110. Thepresurgicallateralization of seizure foci in temporal lobe epilepsy using neuropsychological methods

Thepresurgicallateralization of seizure foci in temporal lobe epilepsy using neuropsychological methods Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

111. Self-management strategies for epilepsy

Self-management strategies for epilepsy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures

2018 PROSPERO

112. Mortality in epilepsy: a systematic review of systematic reviews

Mortality in epilepsy: a systematic review of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

113. Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations

Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

114. Complications after anterior temporal lobectomy for medically intractable epilepsy: a systematic review and meta-analysis

Complications after anterior temporal lobectomy for medically intractable epilepsy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

115. Cortisol levels and seizures in adults with epilepsy: a systematic review

Cortisol levels and seizures in adults with epilepsy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

116. Behavioural and emotional outcomes after paediatric epilepsy surgery: a systematic review

Behavioural and emotional outcomes after paediatric epilepsy surgery: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

117. Screening, diagnosis and Management of ADHD in children with epilepsy

Screening, diagnosis and Management of ADHD in children with epilepsy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

118. Cannabidiol (CBD) in the treatment of infantile epilepsy: systematic review with metanalysis

Cannabidiol (CBD) in the treatment of infantile epilepsy: systematic review with metanalysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

119. Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review

Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2018 PROSPERO

120. Noninvasive presurgical diagnostic tests in lesional drug-resistant epilepsy patients

Noninvasive presurgical diagnostic tests in lesional drug-resistant epilepsy patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO